REFERENCES
1 Dorasala SP, Dorasala S. Medicated Gelfoam for the treatment of recalcitrant otomycosis. Indian J Otol 2013;19:18-9.
2 Abdelazeem M, Gamea A, Mubarak H, Elzawawy N. Epidemiology, causative agents, and risk factors affecting human otomycosis infections. Turk J Med Sci 2015;45(4):820-6.
3 Rosenfeld RM, Brown L, Cannon CR, Dolor RJ, Ganiats TG, Hannley M, et al. American Academy of Otolaryngology–Head and Neck Surgery Foundation. Clinical practice guideline: acute otitis externa. Otolaryngol Head Neck Surg 2006;134(4 suppl):S4–S23.
4 Carney AS. Otitis externa and otomycosis. In: Gleeson M, Browning GG, Burton MJ, Clarke R, Hibbert J, Jones NS, Lund V, Luxon LM, Watkinson JC, editors. Scott-Brown’s Otorhinolaryngology, Head and Neck Surgery. 7th ed. Vol 3. Great Britain: Hodder Arnold; 2008. p. 3351-7.
5 Arndal E, Glad H, Homoe P. Large discrepancies in otomycosis treatments in private ear, nose and throat clinics in Denmark. Dan Med J 2016;63(5):A5231.
6 Agarwal P, Devi LS. Otomycosis in a rural community attending a tertiary care hospital: assessment of risk factors and identification of fungal and bacterial agents. J Clin Diagn Res 2017;11(6):DC14-8.
7 Li Y, He L. Diagnosis and treatment of otomycosis in Southern China. Mycoses 2019;62(11):1064-8.
8 Koltsidopoulos P, Skoulakis CE. Otomycosis with tympanic membrane perforation: a review of the literature. Ear Nose Throat J 2020;99(8):518-21.
9 Anwar K, Gohar MS. Otomycosis: clinical features, predisposing factors and treatment implications. Pak J Med Sci 2014;30(3):564-7.
10 Ali K, Hamed MA, Hassan H, Esmail A, Sheneef A. Identification of fungal pathogens in otomycosis and their drug sensitivity: our experience. Int Arch Otorhinolaryngol 2018;22(4):400-3.
11 Nandyal CB, Choudhari AS. Evaluation of therapeutic efficiency of topical clotrimazole and topical miconazole in the treatment of otomycosis - a prospective study. J Med Res 2015;5:145-9.
12 Lee A, Tysome JR, Saeed SR. Topical azole treatments for otomycosis. Cochrane Database Syst Rev 2021;5(5):CD009289 (Updated version).
13 Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 Statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.
14 Nagl M, Arnitz R, Lackner M. N-Chlorotaurine, a promising future candidate for topical therapy of fungal infections. Mycopathologia 2018;183:161-70.
15 Arifullah, Hassan SZ, Din I. Predisposing factors and treatment outcome of otomycosis. J Gandhara Med Dent Sci 2016;2:27-31.
16 Jimenez-Garcia L, Celis-Aguilar E, Díaz-Pavón G, Muñoz Estrada V, Castro-Urquizo Á, Hernández-Castillo N, et al. Efficacy of topical clotrimazole vs. topical tolnaftate in the treatment of otomycosis. A randomized controlled clinical trial. Braz J Otorhinolaryngol 2020;86(3):300-7.
17 Kiakojuri K, Rajabnia R, Mahdavi Omran S, Pournajaf A, Karami M, Taghizadeh Armaki M. Role of clotrimazole in prevention of recurrent otomycosis. Biomed Res Int 2019;26:5269535.
18 Kiakojori K, Roushan MR, Sepidgar SA. Suction clearance and 2% topical miconazole versus the same combination with acidic drops in the treatment of otomycosis. Southeast Asian J Trop Med Public Health 2007;38(4):749-53.
19 Sander R. Otitis externa: a practical guide to treatment and prevention. Am Fam Physician 2001;63(5):927-36, 941-2.
20 Mishra P, Sachdeva S, Kaushik M, Aggrawal D. Otomycosis treatment: topical drops vs. cream – a prospective randomised study. Clin Surg 2017;2:1747.
21 Özcan KM, Sitesi Y, Blok A. The efficacy of boric acid in otomycosis: an in-vitro study. Mediterr J Otol 2005;2:00-00.
22 Chisholm EJ, Kuchai R, McPartlin D. An objective evaluation of the waterproofing qualities, ease of insertion and comfort of commonly available earplugs. Clin Otolaryngol Allied Sci 2004;29(2):128-32.
23 Lum CL, Jeyanthi S, Prepageran N, Vadivelu J, Raman R. Antibacterial and antifungal properties of human cerumen. J Laryngol Otol 2009;123:375-8.